通化东宝回应美国计划对药品征收关税：未对公司生产经营产生影响

Core Viewpoint - The U.S. has announced a new tariff policy on pharmaceuticals, but the company Tonghua Dongbao is not affected as its products are exempt and it does not currently export to the U.S. [1] Company Impact - Tonghua Dongbao stated that according to the U.S. tariff policy announced on April 2, pharmaceuticals are classified as exempt goods [1] - The company does not have any products exported to the U.S., thus the new tariff policy has no impact on its production and operations [1] - The company's overseas revenue is projected to be approximately 100 million yuan in 2024, which represents a small proportion of total revenue [1] Market Environment - The countries to which Tonghua Dongbao currently exports are all part of the "Belt and Road" initiative, indicating a relatively stable policy environment [1] - The company will continue to monitor international environmental changes and respond flexibly to the complex and changing external environment to ensure long-term stable development [1]